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Introduction
Failure to respond to controlled ovarian hyperstimula-
tion (COH) is still a major concern in assisted reproduc-
tion and there is no consensus on the choice of ovarian
stimulation regimen for poor responders. Many strategies
have been assayed to improve outcomes. Strategies have
ranged from high follicle stimulating hormone (FSH)
dose [1], a combination of clomiphene citrate and hu-
man menopausal gonadotropin (hMG) [2], microdose
gonadotropin-releasing hormone (GnRH) agonist flare
protocol (MF) [3], stop GnRH-agonist protocol [4],
addition of growth hormone [5], use of GnRH antago-
nists [6], and even a natural cycle [7], but the improve-
ment in pregnancy rate has been quite small. The MF
protocol has been used widely in poor responders [8].
Recently GnRH antagonists have been administered
to poor responders with contradictory results [9,10].
In the absence of prior pituitary gonadotropin down
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SUMMARY
Objective: To evaluate and compare the efficacy of microdose gonadotropin-releasing hormone (GnRH) agonist
flare (MF) and GnRH antagonist/letrozole protocols in poor responders undergoing in vitro fertilization.
Materials and Methods: A total of 94 poorly responding patients were randomized in an ovarian stimulation
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and flexible GnRH antagonist protocol.
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oocytes retrieved and metaphase II oocytes retrieved, serum estradiol level on the day of human chorionic
gonadotropin administration, and the percentage of top and good quality embryos were significantly higher in
the MF group. The endometrial thickness, fertilization rate, and the number of embryos transferred were similar in
both groups. The implantation and clinical pregnancy rates were higher in the MF group and the total cancellation
rate was higher in the GnRH antagonist/letrozole group, but these findings were not statistically significant.
Conclusion: The addition of letrozole to the GnRH antagonist for poor responders does not improve the outcome
of assisted reproductive technology cycles. The MF protocol remains the most appropriate protocol in poor
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regulation, the dose of gonadotropins may be reduced
in GnRH antagonist protocols. Letrozole is an aroma-
tase inhibitor and by blocking estradiol (E2) synthesis
decreases negative feedback and increases endogenous
gonadotropin secretion [11]. Furthermore, letrozole
causes an increase in intraovarian androgens and FSH
receptor expression on granulosa cells, thus improving
ovarian response to FSH in poor responders [12]. Co-
administration of letrozole and GnRH antagonists for
COH in poor responders may enhance the pregnancy
rate in assisted reproductive technology cycles, there-
fore we designed a randomized controlled trial study
to evaluate the GnRH antagonist/letrozole (A/L) and
MF protocols in poor responders undergoing in vitro
fertilization (IVF) cycles.
Materials and Methods
Patients
This study was a prospective controlled trial with 94
poor responders who were admitted to our IVF center
between November 1, 2007, and November 1, 2008. The
study was reviewed and approved by the ethics com-
mittee of the Research and Clinical Center for Infertility
(Yazd University of Medical Science). Written informed
consent was obtained from all patients. The inclusion
criteria were to have at least one previous failed IVF
cycle in which three or fewer follicles with a mean diam-
eter of 16 mm were achieved and/or serum E2 levels
measured on the day of human chorionic gonadotropin
(hCG) administration was 500 pg/mL or less. Patients
exhibiting a day 3 serum FSH level greater than or
equal to 12 mIU/mL were excluded; there was no age
limit for inclusion in the study. Patients were random-
ized to an ovarian stimulation regime with either an MF
or A/L protocol. A method of computer generated
randomization was used. The primary outcome was to
compare the clinical pregnancy rate in those protocols.
Treatment protocols
All women received 21 days of an oral contraceptive. 
A MF protocol was used for ovarian stimulation in 
49 patients. Three days after the last pill, subcutaneous
administration of a GnRH-agonist, buserelin (Suprefact;
Aventis Pharma, Frankfurt, Germany), at a dose of 50 μg
twice daily was initiated. Two days after that, recombi-
nant FSH (Gonal-F; Serono, Aubonne, Switzerland) or
hMG (Merional; IBSA, Lugano, Switzerland) at 300–
450 IU/day was administered. Forty-five patients were
assigned to an A/L protocol. After oral contraceptive
withdrawal bleeding on day 3 of the cycle, recombi-
nant FSH or hMG at 300–450 IU/day was initiated and
letrozole (Femara; Novartis, East Hanover, NJ, USA) at
5 mg/day was administered for 5 days. When the dom-
inant follicle reached 14 mm in mean diameter, subcu-
taneous ganirelix acetate (Antagon; Organon, West
Orange, NJ, USA) treatment at 0.25mg daily was started.
Patients were monitored by serial vaginal ultrasonog-
raphy and measurement of serum E2 levels. When at
least two follicles with a mean diameter of 18 mm were
observed, 10,000 IU hCG (Pregnyl; Organon, Oss, the
Netherlands) was administered. Cycle cancellation was
considered when fewer than two follicles with normal
growth pattern were noted.
Oocyte retrieval was performed 34–36 hours after
hCG administration. Conventional IVF or intracytoplas-
mic sperm injection was performed as appropriate.
Embryos with 4–6 equal-sized and evenly shaped blas-
tomeres on day 2 with 20% fragmentation or less and no
multinucleation were considered top quality embryos.
Embryos with 2–6 even or uneven blastomeres with 20%
fragmentation or less and no multinucleation were con-
sidered good quality embryos. Embryos were transferred
on day 2 or 3 under ultrasound guidance with a C.C.D.
embryo transfer catheter (Laboratoire C.C.D., Paris,
France). Luteal support with intramuscular administra-
tion of progesterone in oil (Progesterone; Aburaihan
Co., Tehran, Iran) at 100 mg daily was started on the
day of oocyte retrieval. Serum β-hCG level was meas-
ured 14 days after embryo transfer and a transvaginal
ultrasonography was performed 3 weeks after a posi-
tive β-hCG result for documentation of gestational sac
and fetal heart activity. Clinical pregnancy was consid-
ered as the presence of a gestational sac with fetal
heart activity.
Statistical analysis
Data were expressed as mean ± standard deviation.
The Student’s t test and χ2 test were used for analysis
as appropriate. A p value less than 0.05 was consid-
ered statistically significant. SPSS version 15.0 (SPSS
Inc., Chicago, IL, USA) was used for data analysis.
Results
Patient characteristics are shown in Table 1. There were
no significant differences among the groups with re-
spect to women’s age (33.8 years vs. 33.5 years), body
mass index (23.8 kg/m2 vs. 24.3 kg/m2), basal FSH
(8.3 mIU/mL vs. 7.9 mIU/mL) and E2 (66.2 pg/mL vs.
63.5 pg/mL) levels, duration of infertility (9.9 years vs.
8.8 years), and number of previous failed IVF cycles
(1.64 vs. 1.63). Infertility etiology distribution did not
differ between groups.
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The results of COH are shown in Table 2. Mean
FSH/hMG dose expressed as the number of 75 IU am-
poules administered (42.1 vs. 46.1), the length of stim-
ulation (8.5 days vs. 9.2 days), mean E2 level on the 
day of hCG administration (477 pg/mL vs. 1,065 pg/
mL), the number of mature follicles (4.2 vs. 5.6), the
number of oocytes retrieved (2.8 vs. 4.4), the number
of metaphase II oocytes retrieved (2.4 vs. 4.1), and the
percentage of top and good quality embryos (31.4% vs.
55.8%) were significantly higher in the MF group. There
was no significant difference in the endometrial thick-
ness (8.3 mm vs. 8.4 mm), percentage of intracytoplas-
mic sperm injection performance (48.8% vs. 51.2%),
fertilization rate (67.3% vs. 70.7 %), and the number of
embryos transferred (1.7 vs. 2.0) between two groups.
Cycle outcomes are shown in Table 3. The implan-
tation rate (3.8% vs. 7.7%) and clinical pregnancy rate
(4.4% vs. 12.2%) was higher in the MF group. The total
cancellation rate (22.2% vs. 12.2%) was higher in the
A/L group but these findings were not statistically 
significant.
Discussion
The results of this prospective randomized trial showed
that the A/L protocol did not improve the implanta-
tion and pregnancy rates in poor responders. Although
the days of stimulation and the dose of gonadotropin
administered were lower in the A/L group, the total
cancellation rate was higher in this group than the MF
group. Furthermore, the stimulation outcomes did not
improve.
There is no consensus on the use of GnRH antago-
nists in poor responders. In a randomized controlled
trial performed in poor responders, ongoing pregnancy
rate was significantly higher in the antagonist group,
compared with the flare GnRH agonist group [13].
A meta-analysis found no difference between GnRH
antagonist and agonist (long and flare up) protocols
with respect to the cycle cancellation, number of mature
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Table 1. Basal characteristics of patients*
A/L (n = 45) MF (n = 49) p
Age (yr) 33.8 ± 5.9 33.5 ± 6.0 NS
BMI (kg/m2) 23.8 ± 2.8 24.3 ± 2.4 NS
Day 3 FSH (mIU/mL) 8.3 ± 2.2 7.9 ± 2.4 NS
Day 3 E2 (pg/mL) 66.2 ± 34.0 63.5 ± 30.7 NS
No. of previous IVF 1.64 ± 0.7 1.63 ± 0.7 NS
Duration of infertility (yr) 9.9 ± 5.1 8.8 ± 5.3 NS
Causes of infertility (%)
Male factor 46.7 46.9 NS
Tubal factor 15.6 16.3 NS
Anovulation 11.1 10.2 NS
Endometriosis 8.9 10.2 NS
Unexplained 17.8 16.3 NS
*Data are presented as mean ± standard deviation or %. A/L = antagonist/
letrozole protocol; MF = microdose GnRH flare protocol; BMI = body mass
index; E2 = estradiol; FSH = follicle stimulating hormone; IVF = in vitro fertil-
ization; NS = not significant.
Table 2. Outcomes of ovarian stimulation*
A/L (n = 45) MF (n = 49) p
Duration of stimulation (d) 8.5 ± 1.1 9.2 ± 1.2 0.007
Gonadotropin dose (No. of 75 IU ampoules) 42.1 ± 7.5 46.1 ± 7.1 0.009
E2 level on day of hCG administration (pg/mL) 477 ± 54 1,065 ± 706 0.000
Endometrial thickness (mm) 8.3 ± 1.3 8.4 ± 1.2 NS
Mature follicle (n) 4.2 ± 3.4 5.6 ± 3.0 0.035
Oocytes retrieved (n) 2.8 ± 2.7 4.4 ± 2.7 0.008
M II oocyte retrieved (n) 2.4 ± 2.4 4.1 ± 2.4 0.001
Fertilization rate (%) 67.3 70.7 NS
ICSI performance (%) 48.6 51.2 NS
Embryo transferred (n) 1.7 ± 1.0 2.0 ± 0.7 NS
Top and good quality embryo (%) 31.4 55.8 0.040
*Data are presented as mean ± standard deviation, n or %. A/L = antagonist/letrozole protocol; MF = microdose flare GnRH agonist protocol; E2 = estradiol; 
M II oocytes = metaphase II oocytes; ICSI = intracytoplasmic sperm injection; NS = not significant.
Table 3. Cycle outcome characteristics*
A/L (n = 45) MF (n = 49) p
Implantation rate (%) 3.8 7.7 NS
Clinical pregnancy 4.4 12.2 NS
rate (%)
Clinical pregnancy 5.3 14.3 NS
rate/ET (%)
Total cancellation 22.2 12.2 NS
rate (%)
*Data are presented as %. A/L = antagonist/letrozole protocol; MF = microdose
GnRH flare protocol; ET = embryo transfer; NS = not significant.
oocytes, and clinical pregnancy rate in poor respon-
ders [14].
Demirol et al showed that a MF protocol appeared
to have a better outcome in poor responders who had
a significantly higher implantation rate when compared
with an antagonist protocol [15]. Mittwally and Casper
reported that aromatase inhibition with letrozole re-
duced the FSH dose required for COH and improved
the ovarian response to FSH in poor responders [11].
Garcia-Velasco et al showed that the addition of letro-
zole to an antagonist gonadotropin protocol in poor res-
ponders improved the pregnancy rate, but this finding
was not statistically significant. In their study the implan-
tation rate was enhanced significantly [16]. Schoolcraft
et al demonstrated that ongoing pregnancy rates were
significantly higher in the MF group than the A/L group
with trends toward increased implantation and lower
cancellation rates also noted, but these were not sta-
tistically significant [17].
Recently, Yarali et al in a retrospective study showed
that the total gonadotropin consumption, duration of
stimulation, E2 level on the day of hCG administration,
and the number of oocytes retrieved were significantly
lower with the A/L protocol compared with the MF
protocol. However, the fertilization rate and the rate
of at least one top-quality embryo transferred was higher
with the A/L protocol compared with the MF protocol.
The clinical pregnancy rates were comparable between
the two groups [18].
The results of our study demonstrated poorer out-
come in the A/L group. Lossl et al demonstrated short-
term androgen priming by the use of an aromatase
inhibitor in COH caused an increased testosterone level
and decreases in both the E2:testosterone ratio and
inhibin B level in follicular fluid (FF) [19]. A higher ratio
of E2:androgen in pre-ovulatory FFs reflects both good
follicular health and the viability of oocytes [20], and
the pre-ovulatory FF level of inhibin B was positively
associated with embryo score. This suggests that the
granulosa cells of the androgen-primed follicle func-
tioned sub-optimally and the aromatase inhibitor was
perhaps not fully cleared from the follicular environment
[19]. These data emphasize the importance of qualita-
tive changes in these patients’ oocytes. Therefore, the
lower fertilization, implantation, and pregnancy rates in
the A/L group may be related to impaired oocyte qual-
ity and lower embryo score. It is unclear whether the
change of protocol and reduction in the dose and dura-
tion of letrozole administration may improve outcomes.
Further studies with a larger sample size would be nec-
essary to verify these questions.
The safety of aromatase inhibitors for pregnancy out-
come in assisted reproduction has been raised. Tulandi
et al compared 514 children born after ovarian stimu-
lation including letrozole with 397 children born after
the use of clomiphene citrate and found no increase in
the number of malformations when letrozole was
administered [21].
In conclusion, our study showed that the addition
of letrozole to the GnRH antagonist protocol did not
improve outcomes in poor responders, and we recom-
mend the MF protocol as a preferred regimen for COH
in patients undergoing assisted reproductive technol-
ogy cycles. Much work remains to be done in optimiz-
ing the A/L protocol and individualizing it to different
cycle characteristics. Furthermore, large, prospective
randomized studies are needed to introduce a regimen
for COH in poor responders that not only increases the
quantitative ovarian response but also enhances the
quality of the developing cohort of oocytes.
Acknowledgments
The authors especially thank Hossein Fallahzadeh for
his assistance in the statistical analysis of the data.
References
1. Karande VC, Jones GS, Veeck LL, Muasher SJ. High dose
follicle-stimulating hormone stimulation at the onset of the
menstrual cycle does not improve the in vitro fertilization out-
come in low-responder patients. Fertil Steril 1990;53:486–9.
2. Saadat P, Slater CC, Jain JK, Tourgeman DE, Stanczyk FZ,
Paulson RJ. Treatment-associated serum FSH levels in very
poor responders to ovarian stimulation. J Assist Reprod Genet
2003;20:395–9.
3. Scott RT, Navot D. Enhancement of ovarian responsiveness
with microdoses of gonadotropin-releasing hormone agonist
and follicle-stimulating hormone during ovulation induction
for in vitro fertilization. Fertil Steril 1994;61:880–5.
4. Faber BM, Mayer J, Cox B, Jones D, Toner JP, Oehninger S,
Muasher SJ. Cessation of gonadotropin-releasing hormone
agonist therapy combined with high-dose gonadotropin
stimulation yields favourable pregnancy results in low
responders. Fertil Steril 1998;69:826–30.
5. Hughes JN, Torresani T, Herve F, Martin-Pont B, Tamboise A,
Santarelli J. Interest of growth hormone-releasing hormone
administration for improvement of ovarian responsiveness
to gonadotropins in poor responder women. Fertil Steril
1991;55:945–51.
6. Akman MA, Erden HF, Tosan SB, Bayazi N, Akoy E, Bahceci
M. Comparison of agonist flare- up- protocol and antago-
nistic multiple dose protocol in ovarian stimulation of poor
responders: results of a prospective randomized trial. Hum
Reprod 2001;16:868–70.
7. Bassil S, Godin PA, Donnez J. Outcome of in vitro fertiliza-
tion through natural cycles in poor responders. Hum Reprod
1999;14:1262–5.
Taiwan J Obstet Gynecol • September 2010 • Vol 49 • No 3300
R. Davar, et al
8. Malmusi S, La Marca A, Guilini S, Xella S, Tagliasacchi D,
Marsella T, Volpe A. Comparison of a gonadotropin-releasing
hormone (GnRH) antagonist and GnRH agonist flare up
regimen in poor responders undergoing ovarian stimulation.
Fertil Steril 2005;84:402–6.
9. Berger BM, Ezcurra D, Alper MM. The agonist-antagonist
protocol: a novel protocol for treating the poor responder.
Fertil Steril 2004;82(Supp 2):S126. [Abstract]
10. Fasouliotis SJ, Laufer N, Sbbagh-Ehrlich S, Lewin A, Hurwiz
A, Simon A. Gonadotropin-releasing hormone (GnRH)-
antagonist vesus GnRH-agonist in ovarian stimulation of
poor responders undergoing IVF. J Assist Reprod Genet 2003;
20:455–60.
11. Mitwally M, Casper R. Aromatase inhibition improves ovar-
ian response to follicle stimulation hormone in poor res-
ponders. Fertil Steril 2002;77:776–80.
12. Weil S, Vendola K, Zhoe J, Bondy CA. Androgen and follicle-
stimulating hormone interaction in primate ovarian follicle
development. J Clin Endocrinol Metab 1998;84:2951–6.
13. Lainas TG, Sfontorious IA, Papanicolaou EG, Zorzvilis JZ,
Petsas GK, Lainas GT, Kolibianakis EM. Flexible GnRH
antagonist versus flare-up GnRH agonist protocol in poor
responders treated by IVF: a randomized controlled trial.
Hum Reprod 2008;23:1355–8.
14. Franco JG, Baruffi RL, Mauri AL, et al. GnRH agonist versus
GnRH antagonist in poor ovarian responders: a meta-
analysis. Reprod Biomed Online 2006;13:618–27.
15. Demirol L, Williams DB, Robins JC, Maxwell RA, Thomas MA.
Comparison of microdose flare-up and antagonist multiple
dose protocols in poor responder patients. Fertil Steril 2005;
84:S325. [Abstract]
16. Garcia-Velasco J, Moreno L, Pacheco A, Guillen A, Duque L,
Requena A, Pellicer A. The aromatase inhibitor letrozole
increases the concentration of intraovarian androgens and
improves in vitro fertilization outcome in low responder
patients: a pilot study. Fertil Steril 2005;84:82–7.
17. Schoolcraft W, Surry E, Minjarez D, Stevens J, Gardner D.
Management of poor responders: can outcomes be improved
with a novel gonadotropin-releasing hormone antagonist/
letrozole protocol? Fertil Steril 2008;89:151–6.
18. Yarali H, Esinler I, Polat M, Bozdag G, Tiras B. Antagonist/
letrozole protocol in poor ovarian responders for intracyto-
plasmic sperm injection: a comparative study with the micro-
dose flare-up protocol. Fertil Steril 2008;92:231–5.
19. Lossl K, Yding Anderson C, Loft A, Freiesleben NLC,
BangsbØll S, Nyboe Anderson A. Short term androgen
priming by use of aromatase inhibitor and hCG before con-
trolled ovarian stimulation for IVF. A randomized con-
trolled trial. Hum Reprod 2008;23:1820–9.
20. McNatty KP, Smith DM, Makris A, Osthanondh R, Ryan KJ.
The microenvironment of the human antral follicle: interre-
lationships among the steroid levels in antral fluid, the
popularity of granulosa cells, and the status of the oocytes
in vivo and in vitro. J Clin Endocrinol Metab 1979;49:851–60.
21. Tulandi T, Martin J, Al-Fadhi R, et al. Congenital malforma-
tion among 911 newborns conceived after infertility treat-
ment with letrozole or clomiphene citrate. Fertil Steril 2006;
85:1761–5.
Taiwan J Obstet Gynecol • September 2010 • Vol 49 • No 3 301
Antagonist/Letrozole in Poor IVF Responders
